OBJECTIVE: The receptor for advanced glycation end products mediates a variety of inflammatory responses. Soluble receptor for advanced glycation end products has been suggested to function as a decoy abrogating cellular activation. High-mobility group box 1 is a high-affinity binding ligand for the receptor for advanced glycation end products with cytokine activities and plays a role in sepsis. DESIGN: Controlled, in vivo laboratory study. SETTING: Research laboratory of a health sciences university. SUBJECTS: C57BL/6 mice. INTERVENTIONS: Peritonitis was induced by intraperitoneal injection of Escherichia coli. Mice received soluble receptor for advanced glycation end products or anti-high-mobility group box 1 immunoglobulin G, or the appropriate control treatment. MEASUREMENTS AND MAIN RESULTS: Soluble receptor for advanced glycation end products-treated mice demonstrated an enhanced bacterial dissemination to liver and lungs, accompanied by increased hepatocellular injury and exaggerated systemic cytokine release, 20 hrs after intraperitoneal administration of Escherichia coli. Soluble receptor for advanced glycation end products administration in healthy, uninfected mice did not induce an immune response. Remarkably, lung inflammation was unaffected. Furthermore, high-mobility group box 1 release was enhanced during peritonitis and anti-high-mobility group box 1 treatment was associated with higher bacterial loads in liver and lungs. CONCLUSIONS: These data are the first to suggest that receptor for advanced glycation end products ligands, including high-mobility group box 1, limit bacterial dissemination during Gram-negative sepsis.
OBJECTIVE: The receptor for advanced glycation end products mediates a variety of inflammatory responses. Soluble receptor for advanced glycation end products has been suggested to function as a decoy abrogating cellular activation. High-mobility group box 1 is a high-affinity binding ligand for the receptor for advanced glycation end products with cytokine activities and plays a role in sepsis. DESIGN: Controlled, in vivo laboratory study. SETTING: Research laboratory of a health sciences university. SUBJECTS: C57BL/6 mice. INTERVENTIONS:Peritonitis was induced by intraperitoneal injection of Escherichia coli. Mice received soluble receptor for advanced glycation end products or anti-high-mobility group box 1 immunoglobulin G, or the appropriate control treatment. MEASUREMENTS AND MAIN RESULTS: Soluble receptor for advanced glycation end products-treated mice demonstrated an enhanced bacterial dissemination to liver and lungs, accompanied by increased hepatocellular injury and exaggerated systemic cytokine release, 20 hrs after intraperitoneal administration of Escherichia coli. Soluble receptor for advanced glycation end products administration in healthy, uninfected mice did not induce an immune response. Remarkably, lung inflammation was unaffected. Furthermore, high-mobility group box 1 release was enhanced during peritonitis and anti-high-mobility group box 1 treatment was associated with higher bacterial loads in liver and lungs. CONCLUSIONS: These data are the first to suggest that receptor for advanced glycation end products ligands, including high-mobility group box 1, limit bacterial dissemination during Gram-negative sepsis.
Authors: S D Yan; H Zhu; A Zhu; A Golabek; H Du; A Roher; J Yu; C Soto; A M Schmidt; D Stern; M Kindy Journal: Nat Med Date: 2000-06 Impact factor: 53.440
Authors: Rosemarijn Renckens; Joris J T H Roelofs; Sandrine Florquin; Alex F de Vos; Jennie M Pater; H Roger Lijnen; Peter Carmeliet; Cornelis van 't Veer; Tom van der Poll Journal: J Immunol Date: 2006-07-15 Impact factor: 5.422
Authors: Anita W Rijneveld; Marcel Levi; Sandrine Florquin; Peter Speelman; Peter Carmeliet; Tom van Der Poll Journal: J Immunol Date: 2002-04-01 Impact factor: 5.422
Authors: A Bierhaus; S Schiekofer; M Schwaninger; M Andrassy; P M Humpert; J Chen; M Hong; T Luther; T Henle; I Klöting; M Morcos; M Hofmann; H Tritschler; B Weigle; M Kasper; M Smith; G Perry; A M Schmidt; D M Stern; H U Häring; E Schleicher; P P Nawroth Journal: Diabetes Date: 2001-12 Impact factor: 9.461
Authors: M A Hofmann; S Drury; B I Hudson; M R Gleason; W Qu; Y Lu; E Lalla; S Chitnis; J Monteiro; M H Stickland; L G Bucciarelli; B Moser; G Moxley; S Itescu; P J Grant; P K Gregersen; D M Stern; A M Schmidt Journal: Genes Immun Date: 2002-05 Impact factor: 2.676
Authors: Huan Yang; Mahendar Ochani; Jianhua Li; Xiaoling Qiang; Mahira Tanovic; Helena E Harris; Srinivas M Susarla; Luis Ulloa; Hong Wang; Robert DiRaimo; Christopher J Czura; Haichao Wang; Jesse Roth; H Shaw Warren; Mitchell P Fink; Matthew J Fenton; Ulf Andersson; Kevin J Tracey Journal: Proc Natl Acad Sci U S A Date: 2003-12-26 Impact factor: 11.205
Authors: Anastasia Z Kalea; Nina Reiniger; Hojin Yang; Maria Arriero; Ann Marie Schmidt; Barry I Hudson Journal: FASEB J Date: 2009-01-22 Impact factor: 5.191
Authors: Guellue Cataldegirmen; Shan Zeng; Nikki Feirt; Nikalesh Ippagunta; Hao Dun; Wu Qu; Yan Lu; Ling Ling Rong; Marion A Hofmann; Thomas Kislinger; Sophia I Pachydaki; Daniel G Jenkins; Alan Weinberg; Jay Lefkowitch; Xavier Rogiers; Shi Fang Yan; Ann Marie Schmidt; Jean C Emond Journal: J Exp Med Date: 2005-02-07 Impact factor: 14.307
Authors: Per M Humpert; Zdenka Djuric; Stefan Kopf; Gottfried Rudofsky; Michael Morcos; Peter P Nawroth; Angelika Bierhaus Journal: Cardiovasc Diabetol Date: 2007-03-07 Impact factor: 9.951
Authors: Jean-Marc Tadié; Hong-Beom Bae; Sami Banerjee; Jaroslaw W Zmijewski; Edward Abraham Journal: Am J Physiol Cell Physiol Date: 2011-10-19 Impact factor: 4.249
Authors: Ahmed Achouiti; Alex F de Vos; Cornelis van 't Veer; Sandrine Florquin; Michael W Tanck; Peter P Nawroth; Angelika Bierhaus; Tom van der Poll; Marieke A D van Zoelen Journal: PLoS One Date: 2016-01-29 Impact factor: 3.240